Abstract
Adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with conventional chemotherapy have dismal outcomes. Novel immunotherapies targeting CD19, including the bispecific T-cell engager blinatumomab and chimeric antigen-receptor T (CAR-T) cells, have revolutionized the treatment of R/R B-ALL. Robust response rates to CAR-T cell therapy after blinatumomab have recently been reported, but it is unknown whether blinatumomab can be effective following failure of anti-CD19 CAR-T cell therapy. Herein, we describe a patient with Philadelphia chromosome-positive B-ALL who relapsed after CD19-directed CAR-T therapy, but subsequently responded to the combination of blinatumomab and the tyrosine kinase inhibitor ponatinib, with the achievement of a complete remission lasting 12 months.
References
1.
Fielding
AK
, Richards
SM
, Chopra
R
, Lazarus
HM
, Litzow
MR
, Buck
G
, et al; Medical Research Council of the United Kingdom Adult ALL Working Party
; Eastern Cooperative Oncology Group
. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
. Blood
. 2007
Feb
;109
(3
):944
–50
.
[PubMed]
0006-49712.
Oriol
A
, Vives
S
, Hernández-Rivas
JM
, Tormo
M
, Heras
I
, Rivas
C
, et al; Programa Español de Tratamiento en Hematologia Group
. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
. Haematologica
. 2010
Apr
;95
(4
):589
–96
.
[PubMed]
0390-60783.
Tavernier
E
, Boiron
JM
, Huguet
F
, Bradstock
K
, Vey
N
, Kovacsovics
T
, et al; GET-LALA Group
; Swiss Group for Clinical Cancer Research SAKK
; Australasian Leukaemia and Lymphoma Group
. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
. Leukemia
. 2007
Sep
;21
(9
):1907
–14
.
[PubMed]
0887-69244.
Thomas
DA
, Kantarjian
H
, Smith
TL
, Koller
C
, Cortes
J
, O’Brien
S
, et al Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy
. Cancer
. 1999
Oct
;86
(7
):1216
–30
.
[PubMed]
0008-543X5.
Kantarjian
H
, Stein
A
, Gökbuget
N
, Fielding
AK
, Schuh
AC
, Ribera
JM
, et al Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
. N Engl J Med
. 2017
Mar
;376
(9
):836
–47
.
[PubMed]
0028-47936.
Martinelli
G
, Boissel
N
, Chevallier
P
, Ottmann
O
, Gökbuget
N
, Topp
MS
, et al Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study
. J Clin Oncol
. 2017
Jun
;35
(16
):1795
–802
.
[PubMed]
0732-183X7.
Park
JH
, Rivière
I
, Gonen
M
, Wang
X
, Sénéchal
B
, Curran
KJ
, et al Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
. N Engl J Med
. 2018
Feb
;378
(5
):449
–59
.
[PubMed]
0028-47938.
Sotillo
E
, Barrett
DM
, Black
KL
, Bagashev
A
, Oldridge
D
, Wu
G
, et al Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy
. Cancer Discov
. 2015
Dec
;5
(12
):1282
–95
.
[PubMed]
2159-82749.
Jacoby
E
, Nguyen
SM
, Fountaine
TJ
, Welp
K
, Gryder
B
, Qin
H
, et al CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
. Nat Commun
. 2016
Jul
;7
(1
):12320
.
[PubMed]
2041-172310.
Gardner
R
, Wu
D
, Cherian
S
, Fang
M
, Hanafi
LA
, Finney
O
, et al Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
. Blood
. 2016
May
;127
(20
):2406
–10
.
[PubMed]
0006-497111.
Rayes
A
, McMasters
RL
, O’Brien
MM
. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy
. Pediatr Blood Cancer
. 2016
Jun
;63
(6
):1113
–5
.
[PubMed]
1545-500912.
Braig
F
, Brandt
A
, Goebeler
M
, Tony
HP
, Kurze
AK
, Nollau
P
, et al Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
. Blood
. 2017
Jan
;129
(1
):100
–4
.
[PubMed]
0006-497113.
Nagel
I
, Bartels
M
, Duell
J
, Oberg
HH
, Ussat
S
, Bruckmueller
H
, et al Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy
. Blood
. 2017
Nov
;130
(18
):2027
–31
.
[PubMed]
0006-497114.
Shah
BD
, Oluwole
OO
, Baer
MR
, Bishop
MR
, Holmes
HE
, Schiller
GJ
, et al Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3, a study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)
. Chicago
: ASCO
; 2018
. 15.
Stock
W
, Luger
S
, Advani
A
, Geyer
S
, Harvey
R
, Mullighan
C
, et al Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. intergroup trial C10403. ASH Annual Meeting Abstracts; San Francisco, California: Blood; 2014
.16.
Slayton
W
, Kairalla
J
, Schultz
K
, Devidas
M
, Helian
S
, Pulsipher
M
, et al Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children’s Oncology Group AALL0622
. Chicago
: ASCO American Society of Clinical Oncology
; 2015
.17.
O’Hare
T
, Zabriskie
MS
, Eide
CA
, Agarwal
A
, Adrian
LT
, You
H
, et al The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
. Blood
. 2011
Nov
;118
(19
):5250
–4
.
[PubMed]
0006-497118.
Maude
SL
, Frey
N
, Shaw
PA
, Aplenc
R
, Barrett
DM
, Bunin
NJ
, et al Chimeric antigen receptor T cells for sustained remissions in leukemia
. N Engl J Med
. 2014
Oct
;371
(16
):1507
–17
.
[PubMed]
0028-479319.
Ribera
JM
, Ferrer
A
, Ribera
J
, Genescà
E
. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
. OncoTargets Ther
. 2015
Jun
;8
:1567
–74
.
[PubMed]
1178-693020.
Cortes
JE
, Kim
DW
, Pinilla-Ibarz
J
, le Coutre
P
, Paquette
R
, Chuah
C
, et al; PACE Investigators
. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
. N Engl J Med
. 2013
Nov
;369
(19
):1783
–96
.
[PubMed]
0028-479321.
Gaur
S
, Torabi
AR
, Corral
J
. Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor
. In Vivo
. 2014
Nov-Dec
;28
(6
):1149
–53
.
[PubMed]
1791-754922.
Abid
MB
, De Mel
S
. Does ponatinib cross the blood-brain barrier?
Br J Haematol
. 2017
Nov
;179
(3
):497
–8
.
[PubMed]
0007-104823.
Sen
R
, Natarajan
K
, Bhullar
J
, Shukla
S
, Fang
HB
, Cai
L
, et al The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2
. Mol Cancer Ther
. 2012
Sep
;11
(9
):2033
–44
.
[PubMed]
1535-716324.
Assi
R
, Kantarjian
H
, Short
NJ
, Daver
N
, Takahashi
K
, Garcia-Manero
G
, et al Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia
. Clin Lymphoma Myeloma Leuk
. 2017
Dec
;17
(12
):897
–901
.
[PubMed]
2152-2650© 2018 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
